论文部分内容阅读
OncoMed公司Ⅱ期临床试验登西珠单抗(demcizumab)治疗胰腺癌未能达到主终点。Ⅱ期临床YOSEMITE试验入选204名转移性胰腺癌患者,分为登西珠单抗伍用白蛋白结合型紫杉醇(Abraxane)和吉西他滨(gem-citabine)组(A组)以及安慰剂加Abraxane和吉西他滨组(B组),比较一线治疗效果。主终点是无病情加重存
OncoMed’s phase II clinical trial of dexcitabine failed to reach its primary endpoint in the treatment of pancreatic cancer. The phase II clinical YOSEMITE trial included 204 patients with metastatic pancreatic cancer who were randomized to receive celecoxib with albumin-conjugated Abraxane and gem-citabine (group A) and placebo plus Abraxane and gemcitabine Group (Group B), the first-line treatment effect. The main endpoint is no illness worsened